Massachusetts-based AI drug discovery startup Valo Health has entered into a multi-year strategic partnership with drug discovery company Charles River Laboratories to develop a new AI-driven platform to accelerate the preclinical discovery and development of novel therapeutics. The terms and financial details of the partnership have not been disclosed.
The new offering, which is expected to launch in the first half of 2022, will combine Valo’s AI-driven computational platform Opal and Charles River’s drug discovery and development capabilities, including medicinal chemistry, pharmacology, safety testing, and investigational new drug (IND) submission. It will be exclusively available from Charles River.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.